Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Decision Resources Group
Current Neurologist-Reported Patient Share for Tecfidera Exceeds that of Genzyme's Aubagio and Novartis's Gilenya Combined, According to Findings from Decision Resources Group
BURLINGTON, Mass., June 12, 2014 /PRNewswire/ -- Decision Resources Group finds that, within one year of commercial availability, 100 percent of surveyed U.S. neurologists have prescribed Biogen Idec's Tecfidera to at least one of their multiple sclerosis (MS) patients, far surpassing the one-year trial rate for Genzyme's Aubagio (69 percent) and Novartis's Gilenya (79 percent), despite the fact that Tecfidera is the third-to-market oral disease-modifying therapy (DMT) for MS. Driven by significant increases wave over wave, neurologist-reported Tecfidera patient share among DMT-treated relapsing-remitting MS (RR-MS) patients has grown to 13 percent and now exceeds that reported for Aubagio and Gilenya combined. Among high Tecfidera prescribers, Tecfidera is anticipated to become the RR-MS patient share leader as it will overtake Teva's Copaxone within the next six months.
Other key findings from the LaunchTrends: Tecfidera Wave 4 (US) report:
Comments from Decision Resources Group Analyst Emma McFadden, Ph.D.:
About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or
registered trademarks of their respective holders.
For more information, contact:
Decision Resources Group
©2012 PR Newswire. All Rights Reserved.
322 Shipyard Boulevard